Apogee Therapeutics, Inc. (APGE) Stock Price & Analysis
Apogee Therapeutics, Inc. (APGE) rose 2.40% to USD 85 as of June 10, 2026 at 00:45 UTC, according to Nexqual real-time market data.
APGE last closed at USD 83.01; the session ranged USD 81.04–85.37 on volume of 630,277 shares. Market capitalization is $6.41B, with a 52-week range of USD 34.34–95.32 (NGM). Source: Nexqual, June 10, 2026 at 00:45 UTC.
Key Statistics (as of June 10, 2026 at 00:45 UTC)
| Price | USD 85 |
|---|---|
| Change | ▲ 2.40% (up) |
| Previous Close | USD 83.01 |
| Open | USD 83.68 |
| Day Range | USD 81.04 – 85.37 |
| 52-Week Range | USD 34.34 – 95.32 |
| Volume | 630,277 shares |
| Market Cap | $6.41B |
| Exchange | NGM |
Technical Analysis (APGE)
Nexqual's technical model rates APGE "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 50.76 (neutral) |
| vs SMA50 | Above (USD 84.18) |
| MACD | 0.55 (positive) |
Analyst Ratings (APGE)
Wall Street analysts rate APGE "Strong Buy" based on 17 analysts, with a mean price target of USD 119.24 (range USD 81–160), per Nexqual as of June 10, 2026 at 00:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 119.24 |
| High Target | USD 160 |
| Low Target | USD 81 |
| Buy / Hold / Sell | 15 / 4 / 0 |
Earnings (APGE)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.89 |
| Revenue Estimate | $15.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.06 vs est -1.13 ▲ beat |
| 2025-12-31 | USD -1.03 vs est -1.04 ▲ beat |
| 2025-09-30 | USD -1.11 vs est -1.15 ▲ beat |
| 2025-06-30 | USD -1.13 vs est -1.05 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Financials & Fundamentals (APGE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -28.47% |
| Debt / Equity | 0.64 |
| Current Ratio | 32.59 |
| Total Cash | $1.06B |
| Total Debt | $8.05M |
| Free Cash Flow | $-142.58M |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Financial Health Score (APGE)
Nexqual rates Apogee Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:45 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $1.06B cash vs $8M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$235M |
| Efficiency | Critical — ROE -28%, ROA -19.0% |
Ownership (APGE)
| Insider Ownership | +9.68% |
|---|---|
| Institutional Ownership | +131.10% |
| Shares Outstanding | 61.90M |
| Float | 57.83M |
| Short % of Float | +19.59% |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Leadership (APGE)
Apogee Therapeutics, Inc. is led by Michael Thomas Henderson (age 35), CEO & Director, per Nexqual as of June 10, 2026 at 00:45 UTC.
| CEO & Director | Michael Thomas Henderson (age 35) |
|---|---|
| Chief Financial Officer | Jane Pritchett V. Henderson (age 59) |
| Vice President of Investor Relations | Noel Kurdi |
| Senior Vice President of Clinical Operations | Wendy Aspden-Curran |
| Senior Vice President of Finance | Monica Forbes (age 49) |
Major Backers & Investors (APGE)
Notable institutional backers of Apogee Therapeutics, Inc. include T. Rowe Price, FMR, LLC, Venrock Adviser, LLC, according to Nexqual as of June 10, 2026 at 00:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 27.53% |
| FMR, LLC | 14.96% |
| Venrock Adviser, LLC | 13.72% |
| Wellington Management | 7.07% |
| RTW Investments LP | 4.49% |
| Fidelity | 3.97% |
| Janus Henderson Group PLC | 3.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.36% |
| BlackRock | 8.29% |
| State Street | 5.54% |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
From Apogee Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe our approach will 10 Table of Contents   enable us to develop a portfolio of therapies that are differentiated compared to the currently available standards of care and address unmet medical needs for I&I indications, including the potential for improved dosing and/or efficacy.
- Our Approach Our goal is to discover and develop new therapies for a range of I&I indications.
Partnerships
- Our Collaboration, License and Services Agreements Paragon Option Agreements In February 2022, we entered into an antibody discovery and option agreement with Paragon, which was subsequently amended in November 2022 (as amended, the "2022 Option Agreement").
- In November 2023, we entered into an additional antibody discovery and option agreement with Paragon (the "2023 Option Agreement" and together with the 2022 Option Agreement, collectively, the "Option Agreements").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | USD 76.44 | ▲ 3.79% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| JANX | Janux Therapeutics, Inc. | USD 13.62 | ▲ 1.95% |
| CGON | CG Oncology, Inc. | USD 56.67 | ▲ 5.49% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:45 UTC. This page is informational and not investment advice.